Ray Anjoul

Tax exemption of employer-provided transit benefits: campaign to allow employers to provide employees with a transit benefit for the journey to work that would be exempted from income tax. National Transit Strategy: development of comprehensive, integrated national policy on public transit, including elements addressing funding, land use, research, incentives and accountability. Municipal infrastructure investment: activity to promote federal investment in municipal infrastructure projects; includes pre-budget recommendations and proposals. Dedicated funding for urban public transit: campaign to implement a dedicated portion of federal funding programs specifically for public transit projects; includes pre-budget recommendations and proposals. Seeking an amendment to the criminal code to strengthen penalties for assaults on transit workers and expand the current definition of transit operators to include all transit workers. Federal investment in public transit safety and security measures.

Supporting PLEAC in advancing its goal to maintain federal funding of provincial public legal education organizations to deliver services in future budgets.

7) Identifying opportunities to engage in consultations, policy reviews, or federal programs relevant to smoking cessation or health innovation. 6) Providing timely information and scientific context related to harm reduction and nicotine pouches; 5) Promoting policy and regulatory approaches that support innovation in smoking cessation 4) Facilitating engagement with Members of Parliament, political staff, and relevant officials at Health Canada, Finance Canada, and the Privy Council Office Targeted Public Office Holders 3) discuss Zonnic as part of a broader harm reduction framework and to promote the role of regulated nicotine replacement therapies (NRTs) in helping adult smokers quit combustible tobacco. 2) Support Imperial Tobacco Canada's public policy engagement strategy related to Zonnic, a nicotine pouch approved by Health Canada. 1) Regulations related to nicotine replacement therapies approved by Health Canada under the Food and Drugs Act (FDA).